Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease.
The Trial
NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial. In this trial, patients are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests. Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer cells. Patients whose tumors have genetic changes that match one of the treatments in the trial may receive that treatment, if they meet other eligibility criteria. The trial seeks to determine whether treating cancer based on these specific genetic changes is effective, regardless of cancer type.
There are several treatment arms that are open to patients at any given time, each one enrolling patients whose tumors have a specific genetic change. Most treatment arms will enroll 35 patients. However, a few treatment arms address more common genetic changes, and for those up to 70 patients per arm will be enrolled. A few more treatment arms are expected to open in the future.
The drugs included in the trial have either been approved by the U.S. Food and Drug Administration (FDA) for another cancer or are still being tested in other clinical trials but have shown some effectiveness against tumors with a particular genetic change.
Types of Cancers Studied
Patients with advanced solid tumors, lymphomas, or myeloma may be eligible for MATCH, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment.
A goal for the study is for about 25% of patients to have rare or uncommon cancers. So far, the trial has exceeded this goal, with about 60% of the enrolled patients having cancers other than colon, rectal, breast, non-small cell lung, or prostate.
How Patients Can Enroll in NCI-MATCH
The only way that new patients can enroll on a MATCH treatment arm is if all of the following conditions are met:
- They are under the care of an oncologist at a participating MATCH site. There are nearly 1,100 sites in the U.S. and Puerto Rico. If the patient is not being treated at one of these sites, their oncologist can refer them to one. See the protocol summary for a complete list.
- Their oncologist orders routine tumor gene testing to help guide treatment decisions from a participating testing lab.
- The lab finds a genetic change in the tumor that is being targeted in the MATCH study.
Patients will not need a new tumor biopsy to take part in this trial. Instead, their oncologist may submit tumor tissue from a prior biopsy.
Once enrolled in a treatment arm, patients will be treated with the targeted drug(s) for as long as their tumor shrinks or remains stable.
For more information about the referral process and participating labs, visit Genomic Testing and the Laboratory Referral Process.
Goals of NCI-MATCH
The primary goal for MATCH is to determine the percentage of patients whose tumors have a complete or partial response to treatment, meaning the tumors shrink by a certain amount. This is called the objective response rate. Treatments will be considered promising if at least 16% of the patients in an arm have tumor shrinkage. This threshold was chosen to reduce the chance that a treatment that is not working will appear promising while also improving the chance that a treatment that is working will appear promising.
A secondary goal for the trial is to determine the percentage of patients whose disease does not worsen for at least six months. This is known as progression-free survival.
In addition to assessing the objective response rate and progression-free survival, researchers will also determine time to progression of the cancer and evaluate the side effects of the treatments.
Treatment Arms that Are Open and Enrolling Patients
| Arm | Targeted Genetic Change | Drug(s) |
|---|---|---|
| A | EGFR mut | Afatinib |
| C2 | MET ex 14 sk | Crizotinib |
| E | EGFR T790M | AZD9291 |
| L | mTOR mut | TAK-228 (formerly MLN0128) |
| T | SMO/PTCH1 mut | Vismodegib |
| V | cKIT mut | Sunitinib |
| Z1E | NTRK fusions | Larotrectinib (LOXO-101) |
| Z1G | PTEN loss without PIK3CA mut | Copanlisib |
| Z1H | PTEN (deleterious) seq result and PTEN exp | Copanlisib |
| Z1K | AKT mut | Ipatasertib |
| Z1L | Non-V600 BRAF mut | Ulixertinib (BVD-523) |
Trial Costs
If patients enroll in a treatment arm, the trial covers the drug used in that arm.
Unless patients are informed that certain tests are being done at no charge, they or their health insurance company will need to cover all other costs, including the cost of tests, procedures, or medicines to manage any side effects of treatment. Participants will not be paid to take part in this study.
Trial Collaborators
NCI-MATCH is supported by NCI and is coordinated by the ECOG-ACRIN Cancer Research Group. Personnel from NCI, ECOG-ACRIN, and the other adult trial groups in the NCI-supported National Clinical Trials Network (NCTN)—the Alliance for Clinical Trials in Oncology, NRG Oncology Group, and SWOG—have collaborated in the development of NCI-MATCH. The NCTN includes researchers, physicians, and health care professionals at public and private institutions across the United States. They conduct clinical trials on all types of adult cancers.
In addition to the institutions belonging to the NCTN, NCI-MATCH will be open to all institutions and sites that participate in the NCI Community Oncology Research Program (NCORP).
For clinical trial tracking purposes, the NCI-MATCH trial is also referred to as EAY131 and as NCT02465060.
To Learn More about NCI-MATCH
To learn more about MATCH, patients should start by speaking with their doctors or healthcare team. More details about MATCH are available in the protocol summary.
Posted:
Updated:
Reviewed:
Syndicated Content Details:
Source URL: https://www.cancer.gov/node/829631/syndication
Source Agency: National Cancer Institute (NCI)
Captured Date: 2015-07-29 16:31:00.0
Source URL: https://www.cancer.gov/node/829631/syndication
Source Agency: National Cancer Institute (NCI)
Captured Date: 2015-07-29 16:31:00.0
No comments